Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: Comparison of efficacy and interaction with indinavir

Infection

Volumn 32, Issue 4, 2004, Pages 229-233

  Benesic, A ^a   Zilly, M ^a   Kluge, F ^a   Weissbrich B ^a   Winzer, R ^a   Klinker, H ^a   Langmann, P ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; DIDANOSINE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; INDINAVIR; LAMIVUDINE; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; NEPHROTOXICITY; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 4043063631     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-004-3136-7     Document Type: Article

References (14)

1. Badiou S, Merle De Boever C, Dupuy AM, Baillat V, Cristol JP, Reynes J: Decrease in LDL-size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity? Atherosclerosis 2003; 168: 107-113.
2. Calza L, Manfredi R, Chiodo F: Hyperlipidaemia in patients with HIV1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Int J Antimicrob Agents 2003; 22: 89-99.
3. Calza L, Manfredi R, Chiodo F: Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 2003; 17: 851-859.
4. Calza L, Manfredi R, Chiodo F: Use of fibrates in the management of hyperlipidaemia in HIV-infected patients receiving HAART. Infection 2002; 30: 26-31.
5. Hui DY: Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 2003; 42: 81-92.
6. Bastard J-P, Caron M, Vidal H, Jan V, Auclair M, Vigoroux C, Luboinski J, Laville M, Maachi M, Girard P-M, Rozenbaum W, Levan P, Capeau J: Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359: 1026-1031.
7. Manfredi R, Chiodo F: Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J Infect 2001; 42: 181-188.
8. Mattacks CA, Sadler D, Pond CM: Site-specific differences in the action of NRTI drugs on adipose tissue incubated in vitro with lymphoid cells, and their interaction with dietary lipids. Comp Biochem Physiol 2003; 135: 11-29.
9. Chong PH , Seeger JD, Franklin C: Clinically relevant differences between the statins: implications for therapeutic selection. Amer J Med 2001; 111: 390-400.
10. Aarnoutse RE, Grintjes KJT, Telgt DSC, Stek M, Hugen PWH, Reiss P, Koopmans PP, Hekster YA, Burger DM: The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Therap 2002; 71: 57-67.
11. Bilia AR, Gallori S, Vicieri FF: St. John's wort and de pression: efficacy, safety and tolerability - an update. Life Sci 2002; 70: 3077-3096.
12. Hamzeh, FM, Benson C, Gerber J, Currier J, McCrea J, Deutsch P, Ruan P, Wu H, Lee J, Flexner C, AIDS Clinical Trials Group 365 Study team: Steady-state pharmacokinetic interaction of modified dose indinavir and rifabutin. Clin Pharmacol Therap 2003; 73: 159-169.
13. Pfister M, Labbe L, Lu J-F, Hammer SM, Mellors J, Bennet KK, Rosenkranz S, Sheiner LB, AIDS Clinical Trials Group Protocol 368 Investigators: Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir. Clin Pharmacol Therap 2002; 72: 133-141.
14. Langmann P, Zilly M, Weißbrich B, Desch S, Väth T, Klinker H: Therapeutic drug monitoring of indinavir in HIV-infected patients undergoing HAART. Infection 2002; 30: 13-16.